Study design (if review, criteria of inclusion for studies)
Secondary analysis of a multicenter, double-blind, randomized, placebo-controlled study.
Participants
Adults with CF hospitalized for an acute pulmonary exacerbation (APE).
Interventions
A high-dose bolus of cholecalciferol (vitamin D (3). Within 72 hours of hospital admission, participants were randomly assigned to a single dose of oral vitamin D (3) (250,000 IU) or placebo, and subsequently, received 50,000 IU of vitamin D (3) or placebo every other week, beginning at month 3 and ending on month 12.
Outcome measures
Glycemic control was assessed by hemoglobin A1c (HbA1c) and fasting blood glucose levels before and 12 months after the study intervention.
Main results
Fifty of the 91 participants in the parent study were eligible for the secondary analysis. There were no differences in 12-month changes in HbA1c or fasting blood glucose in patients randomized to vitamin D or placebo.
Authors' conclusions
A high-dose bolus of vitamin D (3) followed by maintenance vitamin D (3) supplementation did not improve glycemic control in patients with CF.